CTLA4 and neoplasm: CTLA-4 is a negative regulator of T cell activation in the context of antitumor immunity; in preclinical models, monoclonal antibody-mediated inhibition of CTLA-4 leads to tumor regression and long-lasting antitumor immunity [6].